CD137+ and regulatory T cells as independent prognostic factors of survival in advanced non-oncogene addicted NSCLC patients treated with immunotherapy as first-line

CD137+ and regulatory T cells as independent prognostic factors of survival in advanced non-oncogene addicted NSCLC patients treated with immunotherapy as first-line

Abstract Background Immune checkpoint inhibitors (ICIs), administered alone or combined with chemotherapy, are the standard of care in advanced non-oncogene addicted Non-Small Cell Lung Cancer (NSCLC). Despite these treatments' success, most long-term survival benefit is restricted to approxima...

Full description

Bibliographic Details
Main Authors: Alain Gelibter, Angela Asquino, Lidia Strigari, Ilaria Grazia Zizzari, Lucrezia Tuosto, Fabio Scirocchi, Angelica Pace, Marco Siringo, Elisa Tramontano, Serena Bianchini, Filippo Bellati, Andrea Botticelli, Donatella Paoli, Daniele Santini, Marianna Nuti, Aurelia Rughetti, Chiara Napoletano
Format: Article
Language:English
Published: BMC 2024-04-01
Series:Journal of Translational Medicine
Subjects:
NSCLC
Immune checkpoint inhibitors
Pembrolizumab
Immunotherapy
CD137+ T cells
Tregs
Online Access:https://doi.org/10.1186/s12967-024-05142-6

Internet

https://doi.org/10.1186/s12967-024-05142-6

Similar Items